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Abstract 23 
 24 
Following cell entry, the RNA genome of HIV-1 is reverse transcribed into 25 
double-stranded DNA that ultimately integrates into the host cell genome to 26 
establish the provirus. These early phases of infection are notably vulnerable 27 
to suppression by a collection of cellular anti-viral effectors, called restriction 28 
or resistance factors. The host anti-viral protein APOBEC3G (A3G) 29 
antagonizes the early steps of HIV-1 infection through the combined effects of 30 
inhibiting viral cDNA production, and cytidine-to-uridine driven hypermutation 31 
of this cDNA. In seeking to address the underlying molecular mechanism for 32 
inhibited cDNA synthesis, we developed a deep sequencing strategy to 33 
characterize nascent reverse transcription products and their precise 3'-34 
termini in HIV-1 infected T cells. Our results demonstrate site- and sequence-35 
independent interference with reverse transcription, which requires A3G’s 36 
specific interaction with reverse transcriptase (RT) itself. This approach also 37 
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established, contrary to current ideas, that cellular uracil base excision repair 38 
(UBER) enzymes target and cleave A3G-edited uridine-containing viral cDNA. 39 
Together, these findings yield further insights into the regulatory interplay 40 
between RT, A3G and the cellular DNA repair machinery, and identify the 41 
suppression of HIV-1 RT by a directly interacting host protein as a new cell-42 
mediated anti-viral mechanism.  43 
  44 
 3
Introduction 45 
 46 
Prominent among the anti-retroviral restriction factors1,2 are the APOBEC3 47 
(A3) proteins, a family of cytidine deaminases with DNA editing capability3,4. 48 
Humans encode seven A3 proteins of which APOBEC3G (A3G), A3F, A3D 49 
and some allelic forms of A3H are packaged into HIV-1 virions and inhibit 50 
infection5-10. During wild type HIV-1 infection, A3G and other A3 proteins are 51 
largely disabled by the virus-encoded Vif protein, which promotes 52 
proteasomal degradation through recruitment to a CUL5 ubiquitin ligase 53 
complex11-13. Vif is therefore essential for productive HIV-1 replication in its 54 
natural cell targets, CD4-positive T-cells14.  55 
 56 
A3 proteins dramatically alter the nascent DNA products of reverse 57 
transcription in ensuing rounds of infection: these effects are most 58 
pronounced for A3G, which displays the strongest anti-viral phenotype6,15. Not 59 
only is the viral complementary DNA (cDNA) littered with numerous cytidine-60 
to-uridine mutations16-18, but the accumulation of cDNA is also severely 61 
reduced compared to infection in the absence of A3 proteins14,17,19-22. 62 
 63 
Figure 1a illustrates three potential, non-mutually exclusive mechanisms for 64 
A3G anti-viral action. 1) Hypermutation: the post-synthetic deamination of 65 
cytidine to uridine in minus strand reverse transcripts registers as plus strand 66 
guanosine-to-adenosine mutations. At least 10% of guanosines can be 67 
mutated14, which severely compromises viral sequence integrity and is 68 
typically lethal. 2) cDNA fragmentation and degradation: nascent cDNA is 69 
hypermutated as in the first model but with the uracils subsequently 70 
recognized by uracil-DNA glycosylases (UDGs) in the uracil base excision 71 
repair (UBER) pathway, leading to base excision, recognition by abasic site 72 
endonucleases (APE1 or APE2), DNA cleavage and, potentially, degradation. 73 
3) Deamination-independent inhibition of reverse transcription: A3G interferes 74 
with the biosynthetic capability of the reverse transcriptase (RT) enzyme, 75 
reducing the production of cDNA.  76 
 77 
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While A3-mediated hypermutation is well documented3,4, the two latter 78 
mechanisms for reducing cDNA accumulation remain controversial and poorly 79 
understood. Whether UDG-dependent processing of A3G-edited viral DNA 80 
occurs is unresolved. Although reducing levels of the UDG, UNG2, has been 81 
shown to diminish A3G anti-viral activity23,24, other groups have found that 82 
UDGs are dispensable for A3G function and the reduction of cDNA levels25-27. 83 
A3G’s deaminase-independent activity was originally noted when 84 
enzymatically-deficient A3G mutant proteins were shown to exhibit a degree 85 
of anti-viral function and to suppress cDNA production21,28.  86 
 87 
A common observation from studies of the deaminase-independent effects of 88 
A3G is the increasing magnitude of inhibition over the course of reverse 89 
transcription and integration, which implies features of processivity. In addition 90 
to proposals that A3G inhibits specific steps, such as DNA strand transfers 91 
and integration27,29, we have therefore suggested more general interference 92 
with RT-catalyzed nucleic acid polymerization14,20. Conceptually, this could 93 
occur via a “roadblock” mechanism, in which A3G binds the template genomic 94 
RNA and sterically hinders RT translocation, or via direct interference with the 95 
biosynthetic capability of RT (or a combination of both). The first hypothesis is 96 
supported experimentally by in vitro reconstituted primer extension assays 97 
where A3G induces pausing/arrest at specific sites in the U5-R sequence22 98 
and by nucleic acid binding studies using purified A3G30, whereas A3G’s 99 
interaction with RT may lend support to the second31. 100 
 101 
  102 
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Results 103 
 104 
High throughput sequencing strategy for determining 3’-termini of HIV-1 105 
reverse transcripts  106 
We reasoned that defining populations of nascent viral cDNAs produced 107 
during HIV-1 infection would shed light upon the mechanism(s) of A3G-108 
mediated viral inhibition. Here, we developed an Illumina MiSeq™ based 109 
deep sequencing method that enables unbiased mapping of the 3’-termini of 110 
reverse transcription products at single nucleotide resolution in infected T 111 
cells. This protocol focuses on early cDNA species, namely the minus strand 112 
strong stop ((-)sss) intermediate (comprising the U5 and R regions of the 5’-113 
long terminal repeat) and early first strand transfer products32,33(Figure 1b). 114 
The strategy for library creation is depicted in Figure 1c (Supplementary 115 
Figure 1 and online methods). Briefly, T cells are infected with HIV-1, nucleic 116 
acids extracted and then enriched for viral DNA using capture 117 
oligonucleotides. The open 3’-termini of single stranded cDNA are ligated to a 118 
single stranded DNA adaptor (Supplementary Figure 1c), and PCR-amplified 119 
for sequencing. Barcoding is used to discard non-unique reads.  120 
 121 
Profiles of cDNA intermediates in T cells infected with HIV-1ΔVif in the 122 
presence or absence of A3G 123 
To investigate A3G’s effects on reverse transcription, HIV-1ΔVif virions were 124 
produced without, or with low or high amounts of packaged A3G (Figure 1d). 125 
Both infectivity, measured by challenging TZM-bl reporter cells (Figure 1e), 126 
and cDNA accumulation in CEM-SS cells at 4 h post infection, measured by 127 
qPCR of total DNA extracts (Figure 1f), inversely correlated with the level of 128 
packaged A3G. The suppression of cDNA production was characteristically 129 
less pronounced than the inhibition of infectivity20,29,34, presumably because 130 
the latter reflects the cumulative effects of deaminase-dependent and -131 
independent activities.  132 
 133 
The DNA extracts were then used to prepare libraries for sequencing (Figure 134 
1c). We first analyzed cDNA 3’-termini: unique reads for each (-)sss cDNA 3’-135 
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end were counted and divided by total read number, which ranged between 136 
26500 (high A3G) and 81000 (no A3G) (Supplementary Figure 4b), to obtain 137 
relative distributions of cDNA lengths. The top panel in Figure 1g depicts the 138 
profile for HIV-1ΔVif without A3G, with the most abundant species being the 139 
180 nt (-)sss cDNA (>17% in this experiment). The rest of the profile was 140 
notably flat and evenly distributed, with some uplift in the abundance of 141 
shorter cDNAs. This pattern differs substantially from what is seen in 142 
reconstituted primer extension assays where DNA synthesis pauses at 143 
specific sites (Supplementary Figure 3a)35-37. 144 
 145 
The presence of A3G resulted in the appearance of five prominent peaks, 146 
each representing a specific 3’-terminus (Figure 1g, middle and bottom 147 
panels). Importantly, these sites do not match A3G-induced pause sites seen 148 
in reconstituted reactions containing purified A3G (Supplementary Figure 3a, 149 
lanes 6 to 9)22. Instead, these sites lie one nt 5’ to cytidine-to-uridine 150 
mutations identified in longer DNA reads (dashed red lines), and occurring at 151 
consensus A3G editing sites5,16,38,39. These peaks also featured in first strand 152 
transfer sequences, but were absent when catalytically inactive A3G mutant 153 
proteins were tested (Supplementary Figures 4a and 5)28. These observations 154 
suggested that A3G editing hotspots serve as cDNA cleavage sites. 155 
 156 
Target cell UBER enzymes mediate the detection and cleavage of A3G-157 
edited HIV-1 cDNA  158 
To test whether UDGs, specifically UNG240,41, mediate the processing of 159 
uridine-containing cDNA, leading to endonucleolytic cleavage, we utilized the 160 
bacteriophage uracil-DNA glycosylase inhibitor (UGI)42. CEM-SS target cells 161 
and HEK293T producer cells stably expressing codon optimized UGI (hUGI)25 162 
were generated, the latter being required because UNG2 is packaged into 163 
virions43,44. Enzymatic analyses of cell lysates confirmed efficient UDG 164 
suppression (Supplementary Figure 6). HIV-1ΔVif was produced in control or 165 
hUGI expressing HEK293T cells in the absence or presence of A3G (Figure 166 
2a). In bulk measurements of virus infectivity and cDNA abundance (Figures 167 
2b and 2c), no differences were attributable to hUGI, irrespective of 168 
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expression in producer, target or both cultures, reconfirming that UNG2 169 
inhibition does not impact A3G anti-viral function25-27. Sequencing analysis 170 
revealed that UNG2 inhibition in target cells mitigated A3G’s induction of 171 
foreshortened cDNAs, with the overall profiles of 3’-termini resembling those 172 
seen without A3G (Figure 2d; and Supplementary Figure 7).  173 
 174 
We therefore conclude: first, that target cell UNG2 can detect A3G-edited 175 
cDNAs leading to uracil removal and subsequent cleavage (Figure 1a, 176 
pathway 2); second, that UBER-mediated cDNA fragmentation does not lead 177 
to their complete degradation, implying that a deamination-independent 178 
mechanism likely underlies the inhibition of cDNA accumulation by A3G; and, 179 
third, that A3G does not induce site-specific RT pausing, thus arguing against 180 
the aforementioned “roadblock” mechanism for RT inhibition.  181 
 182 
Interaction between A3G and the HIV-1 RT heterodimer 183 
The 3’-termini profiles seen in the absence of A3G, in its presence but with 184 
UNG2 activity abrogated, or with catalytically inactive A3G mutants are very 185 
similar to each other, yet levels of cDNA production differ substantially. One 186 
model to reconcile these observations is for A3G to affect RT processivity 187 
through a mechanism that lacks template sequence specificity. This would 188 
yield similarly reduced nucleotide addition efficiency at all positions, 189 
regardless of RT location on the template RNA. We hypothesized that this 190 
could be achieved through A3G interacting with RT and inhibiting its 191 
enzymatic capability.  192 
 193 
To evaluate this model, we initially used lysates from transfected HEK293T 194 
cells to confirm that A3G co-immunoprecipitates with the HIV-1 RT 195 
heterodimer (p51 and p66 subunits) (Figure 3a)31. Since A3G and RT are 196 
RNA binding proteins, we employed several techniques to ensure that this 197 
interaction is not simply bridged by RNA. First, co-immunoprecipiation assays 198 
were performed in the presence of ribonucleases (Figure 3b); although either 199 
a heterogeneous RNase mixture (upper panel) or RNase A (lower panel) 200 
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noticeably reduced the amount of recovered A3G, the effect was saturable 201 
with A3G pull-down still remaining clear at high RNase levels.  202 
 203 
We next carried out surface plasmon resonance (SPR) assays using purified 204 
p51 and A3G, both stripped of nucleic acids (Supplementary Figure 8). 205 
Measurements provided association and dissociation curves that gave 206 
acceptable fits to a single interaction model (Figure 3c), suggesting that the 207 
majority of complexes were homogeneous in nature. The association rate 208 
constant (kon) was calculated to 1.4 x 103 M-1 s-1, and the dissociation rate 209 
constant (koff) to 2.2 x 10-3 s-1, yielding a dissociation constant (Kd) of ~1.6 μM; 210 
a value close to that calculated using rotational anisotropy (2.3 μM)45. Curve 211 
fitting indicated a maximal binding (Bmax) of ~200 RU of p51. Since the A3G 212 
ligand surface density is ~200 RU this is consistent with a 1:1 binding 213 
stoichiometry for the A3G-p51 complex. Taken together, these findings 214 
indicate that A3G and RT interact directly and that RNA may help to stabilize 215 
the complex. 216 
 217 
Using cell-based FRET assays to measure the A3G-RT interaction 218 
To address further the direct or indirect nature of the A3G-RT interaction, we 219 
turned to fluorescence resonance energy transfer (FRET) assays as they 220 
circumvent any need for protein purification or enrichment. Specifically, we 221 
employed green fluorescent protein (GFP, the donor) and mCherry (the 222 
acceptor) fusion proteins, co-expressed in HeLa cells, together with 223 
fluorescence lifetime imaging microscopy (FLIM) for the FRET readout. Here, 224 
the average lifetime (τ) of the donor is reduced when in a FRET state owing to 225 
the proximity of the acceptor (online methods)46. FRET is shown both as 226 
representative pseudocolored images with blue/green indicating longer τ than 227 
yellow/red colors (Figure 3d and e), and as efficiency percentages (Figure 3f).  228 
 229 
Cells were transfected with vector pairs expressing the indicated fusion 230 
proteins, fixed and analyzed after 24 h. As expected, A3G_GFP localized to 231 
P-bodies, stress granules as well as the cytosol, while the RT subunits were 232 
more evenly distributed across the cytoplasm (Figure 3d and e). The 233 
oligomerization of A3G47-49 and hetero-dimerization of RT subunits provided 234 
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positive controls, each visualized as yellow/orange coloration (Figure 3e, top 235 
row; and Figure 3f). The RNA helicase MOV10, which co-localizes to P-236 
bodies with A3G, but is not thought to interact with A3G directly since co-237 
immunoprecipitation depends on RNA bridging50 served as a negative control. 238 
No change in donor τ was observed, consistent with the lack of a direct A3G-239 
MOV10 interaction. The low FRET efficiency displayed between A3G_GFP 240 
and the oligomerization-deficient W127A_mCherry mutant51 provided further 241 
assay validation(Figure 3e, second row). In clear contrast, co-expression of 242 
A3G_GFP with p51_mCherry or p66_mCherry yielded marked reductions in τ, 243 
demonstrating very close proximity between RT subunits and A3G (Figure 3e, 244 
third row), consistent with a direct protein-protein interaction.  245 
 246 
A3G and RT interact within intact HIV-1 virions 247 
We also adapted our FRET-FLIM system for cell-free, bulk HIV-1 particles 248 
(Figure 4). A3G_GFP was packaged into virions by co-expression with HIV-249 
1ΔVif, and these were purified and immobilized on coverslips, before immuno-250 
staining and FRET analysis. Rather than using protein fusions that could 251 
interfere with viral assembly or particle, RT was detected using a Cy3-labelled 252 
anti-RT Fab fragment. A3G_GFP exhibits a normal GFP lifetime in the 253 
absence of a fluorescent acceptor (Figure 4a) and a positive control of co-254 
packaged A3G_GFP and A3G_mCherry demonstrates the suitability of this 255 
assay for detecting protein-protein interactions within virions (Figure 4b, left 256 
panel, top row; and Figure 4c). A substantial increase in FRET efficiency was 257 
evident when RT was detected with labeled Fab (Figure 4b, right panel, 258 
bottom row; and Figure 4c), which was not seen with other packaged proteins 259 
as acceptors (Vpr_GFP or cyclophilin A_GFP), the antibody-mediated 260 
detection of Capsid protein (p24Gag) (Figure 4b, top right panels; and Figure 261 
4c), or for virions engineered to lack RT (Figure 4b, left panel, bottom row). 262 
These data demonstrate that A3G and RT interact in viral particles, and 263 
support the view that A3G is positioned at the site of reverse transcription.  264 
 265 
Regions of A3G that interact with HIV-1 RT  266 
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Regions of A3G that interact with RT were mapped by co-expression of RT 267 
with a set of A3G-glutathione-S-transferase (GST) fusions and co-268 
immunoprecipitation (Figure 5a). Consistent with earlier results31, full length 269 
A3G and a fragment spanning residues 65 to 132 interacted with RT (lanes 3 270 
and 4). Interestingly, the N-terminal 76 amino acid fragment of A3G also 271 
bound RT (lane 5), with further truncations revealing dependency on the 272 
residues between positions 30 and 42 (lanes 7 and 8). Thus, RT interacts with 273 
two discrete and non-overlapping regions of A3G.  274 
 275 
Double alanine scanning mutagenesis between residues 30 and 42 in the 276 
context of full length A3G showed that a W34A/L35A double mutant, and 277 
subsequently the single L35A mutant, were impaired for interacting with RT 278 
(Figure 5b). These mapping data were confirmed in intact cells, as the 279 
substitution of leucine at position 35 with alanine (W34A/35A and L35A 280 
mutants) significantly reduced FRET efficiency (Figure 5c, row 3 and 4 and 281 
Figure 5d). As a control, the R24A mutation in A3G, which disrupts a 282 
positively charged patch at the A3G dimer interface52 and inhibits RNA 283 
binding51 (Supplementary Figure 3c) was shown not to alter binding to RT 284 
(Figure 5b, c and d), thereby reinforcing the conclusion that the A3G-RT 285 
interaction is RNA independent. Importantly, like R24A51, the L35A protein 286 
maintains full enzymatic activity as measured in an E. coli-based DNA editing 287 
assay (Supplementary Figure 9), indicating that these substitutions do not 288 
cause global structural defects or misfolding. 289 
 290 
Inhibition of the RT interaction diminishes A3G anti-viral activity 291 
Derivation of a mutation in A3G that interferes with RT binding but maintains 292 
deaminase function allowed us to evaluate directly the importance of the A3G-293 
RT interaction for anti-viral activity. The L35A protein, similar to R24A51, is not 294 
packaged into viruses as efficiently as wild type A3G; however, this defect is 295 
partial and is overcome by increasing protein expression in virus producer 296 
cells.  297 
 298 
For these experiments, we used titrations of wild type A3G in producer cells to 299 
yield viruses with a range of packaged A3G levels (Figure 6a; Supplementary 300 
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Figure 10a). These stocks were then used to infect TZM-bl cells to determine 301 
overall infectivity (Supplementary Figure 10b), and CEM-SS cells to measure 302 
cDNA production (Supplementary Figure 10c); fitted curves were generated 303 
that related infectivity or cDNA levels to amounts of packaged A3G 304 
(Supplementary Figure 10d and 10e).  305 
 306 
Viruses carrying the L35A or R24A mutants were prepared in parallel and 307 
analyzed for packaging, infectivity and cDNA production. By extrapolation 308 
along the fitted curves, we compared their effects on infectivity (Figure 6b) 309 
and reverse transcription (Figure 6c) with those of wild type A3G at matched 310 
packaging levels. Over eight experiments, L35A was significantly less anti-311 
viral than A3G, and this was coupled with increased cDNA production. 312 
Critically, R24A displayed equivalent anti-viral activity to wild type A3G at 313 
comparable levels of encapsidation, thus phenotypically distinguishing itself 314 
from L35A. Moreover, the finding that R24A still suppresses reverse 315 
transcription (Figure 6c), while binding RNA less well (Supplementary Figure 316 
3)51, is again consistent with RT suppression not being mediated by the 317 
“roadblock” mechanism.  318 
 319 
To test whether the remaining anti-viral activity of L35A is deaminase 320 
dependent, we combined this change with a mutation, C288S, that ablates 321 
deamination but incompletely prevents anti-viral activity (Figure 6d; and 322 
Supplementary Figures 5, 10g and 10h)27,28. Importantly, the double mutant 323 
(C288S/L35A) displayed a total loss of anti-viral function even at high 324 
expression levels (Figure 6d), underscoring the importance of both attributes 325 
for full A3G activity.  326 
 327 
Lastly, we analyzed the cDNA profiles in CEM-SS cells challenged with HIV-328 
1ΔVif lacking A3G or containing similar levels of wild type A3G, R24A or L35A 329 
(Figure 6a and e). The three profiles obtained with A3G-bearing viruses were 330 
essentially identical, confirming the editing competency of these mutant 331 
proteins and the absence of any site-specific pausing that correlated with 332 
inhibited cDNA synthesis. We therefore conclude that A3G regulates HIV-1 333 
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RT through a direct interaction that impedes enzymatic capability and 334 
suppresses the production of DNA evenly and without sequence or site 335 
specificity (Figure 1a, pathway 3).  336 
337 
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Discussion 338 
 339 
Here, we present a custom method for monitoring the progression of HIV-1 340 
reverse transcription at single nucleotide resolution in infected cells. Our 341 
findings have relevance for understanding not only A3-mediated restriction, 342 
but also fundamental aspects of reverse transcription. In particular, much of 343 
the current knowledge of reverse transcription has been obtained using in 344 
vitro reconstituted systems32,33,53,54 (e.g., Supplementary Figure 3). In 345 
agreement with such studies, we demonstrate a marked accumulation of a 346 
predominant (-)sss species (e.g., Figure 1g)35,55,56, yet defining its precise 3’-347 
terminus has previously been elusive. The abundant (-)sss cDNA we detect 348 
has a single 3’-cytidine (nt position 180), and we presume this to be derived 349 
from the CapG1-form of HIV-1 RNA. This is consistent with the preferential 350 
dimerization and packaging of CapG1 RNA that has a single guanosine at its 351 
5’-terminus, rather than the CapG2- or CapG3-forms that contain two or three 5’-352 
guanosines57,58.  353 
 354 
In contrast to the distinctive (-)sss product seen in living cells and 355 
reconstituted systems, the foreshortened cDNAs that are detected in 356 
reconstitution experiments are negligible in infected cells (Figure 1g; 357 
Supplementary Figure 3). Their formation has been ascribed to RT 358 
pausing/arrest at homopolymeric motifs or RNA secondary structures35-37,59. 359 
These reproducible disparities may reflect: variations in the enzymatic 360 
capabilities of HIV-1 RT in the microenvironment of reverse transcription 361 
complexes in infected cells versus in reconstituted reactions; differences in 362 
the formation of viral genomic RNA secondary and tertiary structures; or the 363 
presence or relative abundance of viral (or host) proteins such as the HIV-1 364 
Nucleocapsid protein at the site of reverse transcription.   365 
 366 
Not surprisingly, experimental system dependent differences extend to the 367 
effects of A3G on reverse transcription. Studies with reconstituted assays had 368 
indicated A3G-induced pausing of RT at specific sites22 (Supplementary 369 
Figure 3a), which helped formulate the “roadblock” model. Critically, our cell-370 
 14
based DNA sequencing approach provided no evidence for localized A3G-371 
induced RT pausing, with the prominent A3G-dependent cDNA peaks being 372 
caused by UBER activity (Figure 2). These findings evoke a sequence- and 373 
site-independent mechanism for the suppression of RT by A3G, and imply: 374 
first, that there are differences in RT’s behavior in the context of HIV-1 375 
infection; and, second, that the A3G-induced pausing that is seen in 376 
reconstituted reactions reflects an assay-specific epiphenomenon.  377 
 378 
Intrinsic to our model for A3G function is its negative regulatory interaction 379 
with RT, which, based on a series of corroborating biochemical, biophysical 380 
and cell-based FRET assays (Figures 3 to 5)31, we consider to be dependent 381 
on direct binding. Purposeful interference with this interaction through 382 
replacement of leucine-35 resulted in a significant loss of anti-viral activity 383 
(Figure 6b and c), with the remaining anti-viral activity of L35A being 384 
attributable to its deaminase function since the C288S/L35A double mutant 385 
displayed a complete loss of anti-viral phenotype (Figure 6d).  386 
 387 
Our sequencing approach also allowed us to examine the effects of UBER on 388 
viral cDNA following exposure to A3G. Although, we reveal UNG2-mediated 389 
uridine excision from deaminated cDNA, our measurements show ensuing 390 
endonucleolytic cleavage is far from complete since substantial proportions of 391 
cytidine-to-uridine edited cDNAs remained intact. (Figures 1, 2 and 6). 392 
Appreciating this inefficiency helps to reconcile the apparent discrepancy 393 
between the predicted degradative fate of deaminated cDNAs (Figure 1a, 394 
mechanism 2) and the lack of persuasive evidence for UDG involvement in 395 
A3G function. Nevertheless, despite the absence of an evident anti-viral effect 396 
in single round infections (Figure 2b), inefficient UBER recognition of edited 397 
cDNA could still play a role in the interplay between HIV-1 and infected cells, 398 
for instance through sensing of aberrant cDNA fragments as a pathogen-399 
associated molecular pattern1,60. How HIV-1 may circumvent this (aside from 400 
Vif induced A3 destruction in virus producing cells) is a matter of conjecture, 401 
but we note that HIV-1 Vpr and its interacting CUL4 ubiquitin ligase induces 402 
UNG2 degradation23,44,61.  403 
 404 
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Uracilation of HIV-1 cDNA can also arise from the misincorporation of dUTP in 405 
place of dTTP during reverse transcription62, especially in non-dividing cells 406 
such as macrophages that have high dUTP:dTTP ratios63,64. UNG2-mediated 407 
recognition of the resulting uracilated viral cDNA suppresses infection, with 408 
restriction being most evident at the level of DNA integration65-68. Interestingly, 409 
and in contrast to observations made with A3G-induced uracilation (Figure 2, 410 
Supplementary Figure 7)25-27, UGI-mediated suppression of UNG2 in the face 411 
of misincorporation-driven uracilation provokes viral rescue65,66. The basis for 412 
this dichotomy remains to be determined, but could relate to variations in the 413 
extent of uracilation, or cell type dependent differences in the efficiency of 414 
UBER-mediated cDNA recognition or the fate/processing of uracilated cDNA. 415 
 416 
Reverse transcription is a vulnerable step in the HIV-1 life cycle: it is highly 417 
susceptible to pharmacological inhibition, and is also suppressed by A3G and 418 
other host cell restriction factors. TRIM5α destabilizes post-entry viral capsids 419 
which compromises the timely onset/completion of reverse transcription69-71, 420 
while the deoxynucleotide triphosphohydrolase SAMHD1 interferes with 421 
reverse transcription by depleting cellular dNTP pools2. In contrast to these 422 
indirect mechanisms, we demonstrate that RT is inhibited by A3G by a distinct 423 
mechanism, namely via a direct protein interaction that impedes biosynthetic 424 
activity. Establishing the concept that HIV-1 RT can be negatively regulated in 425 
this manner raises the possibility that additional cellular factors may modulate 426 
RT72.  427 
 428 
Future directions for this work include determining: how A3G binding to RT 429 
interferes with enzymatic function, how leucine-35 (a residue that is highly 430 
conserved within the A3 family) participates in the RT interaction, and which 431 
regions of RT bind to A3G. Elucidating the macromolecular structure of the 432 
A3G-RT complex will naturally be a major advance, and can assist in 433 
resolving the heretofore elusive structure of full-length A3G73. Finally, by 434 
revealing that a non-virally encoded interacting partner can regulate HIV-1 435 
RT, we highlight a previously unrecognized vulnerability in the enzyme that 436 
may have the potential to be targeted therapeutically.   437 
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Figure Legends 479 
 480 
Figure 1: Effects of A3G on profiles of nascent HIV-1 cDNA products in 481 
infected T cells.  482 
a) Early steps of the HIV-1 life cycle illustrating three proposed anti-retroviral 483 
mechanisms for A3G that are deaminase-dependent (pathways 1 and 2) or -484 
independent (pathway 3). b) Diagram of HIV-1 reverse transcription. The first 485 
full intermediate, (-)sss cDNA, is completed in step 3. PBS: primer binding 486 
site, PPT: polypurine tract. c) Basic steps of sequencing library preparation. 487 
During infection, HIV-1 produces nascent viral cDNAs of increasing length 488 
(see step 2 in b). Sequencing reads reveal precise 3’-termini at the points of 489 
adaptor-viral DNA ligation (red box). d) Immunoblot analysis of HIV-1 virion 490 
lysates from one of six independent virus preparations. ‘Low’ or ‘High’ A3G 491 
refers to producer cell transfection ratios of 1:10 or 1:4, respectively (A3G 492 
expression plasmid to NL4.3/∆Vif). e) Single-cycle virion infectivity measured 493 
by β-galactosidase activity in challenged TZM-bl reporter cells. f) Quantitative 494 
PCR measuring cDNA abundance in CEM-SS cells at 4 h post-infection. For 495 
e) and f) the individual data points with their mean and standard deviation of 496 
eight independent infections from six virus preparations are shown. *** 497 
indicates p-value of <0.0001 in an unpaired, two-tailed t-test with Welch’s 498 
correction performed in GraphPad Prism®.  g) Numbers of unique sequencing 499 
reads ending at each nt of the HIV-1NL4.3 (-)sss cDNA were divided by the total 500 
read number (Supplementary Figure 4b) within each sample to show the 501 
relative abundance of cDNAs for each length between nt positions 23 and 502 
182. Shown in dashed red lines are the percentages of reads carrying C to 503 
T/U mutations at that position (scale on the right y-axis). See Method section 504 
for analysis details. One representative experiment out of three independent 505 
repeats is shown.  506 
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Figure 2: Consequences of UDG inhibition on A3G antiviral phenotype 507 
and cDNA profiles   508 
a) Immunoblot analysis of HIV-1 virion lysates showing increasing amounts of 509 
packaged A3G_HA at constant CA levels for virions produced in the presence 510 
or absence of a codon optimized (humanized) uracil-DNA glycosylase 511 
inhibitor (hUGI). ‘Low’ or ‘High’ A3G refers to a producer cell transfection 512 
ratios of 1:10 or 1:1, respectively (A3G expression plasmid to NL4.3/∆Vif). 513 
One of three independent sets of virus preparations used for b) and c) is 514 
shown.  b) Virion infectivity was evaluated by challenging TZM-bl cells and 515 
measurement of β-galactosidase activity. c) The abundance of (-)sss 516 
containing cDNA in CEM-SS cells at 4 h post-infection was measured by 517 
quantitative PCR. For b) and c) each viral preparation was used to infect 518 
TZM-bl or CEM-SS target cells with or without hUGI, black dots and grey 519 
squares respectively. The individual data points with their mean and standard 520 
deviation for three independent viral preparations and infections are shown. d) 521 
Sequencing reads from a MiSeq™ library run were analyzed and presented 522 
as in Figure 1g. The labeling to the right indicates whether the HEK293T 523 
producer cells (Prod) and/or the CEM-SS target (Target) cells expressed 524 
hUGI. No A3G indicates the absence of A3G in producer cells and high A3G 525 
refers to relative A3G content in the producer cells. Sequencing data are 526 
derived from one representative experiment out of two independent repeats. 527 
  528 
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Figure 3: Interaction of A3G with HIV-1 reverse transcriptase.  529 
Co-immunoprecipiation analysis of A3G_HA binding to FLAG tagged HIV-1 530 
RT. Transfected HEK293T cell lysates were subjected to anti-FLAG 531 
immunoprecipiation, recovered proteins were detected with anti-HA (for A3G), 532 
anti-RT or anti-FLAG antibodies. CD8_FLAG served as an irrelevant protein 533 
control. One representative experiment of three repeats is shown. *HC: 534 
immunoglobulin heavy chain b) RNase resistance of the A3G-RT complex. 535 
Shown are anti-FLAG immunoprecipitations after the bead bound proteins 536 
had been subjected to RNase A or RNase Mix treatment, at the indicated 537 
concentrations, followed by washing and immunoblotting. One representative 538 
experiment of three repeats is shown. Samples without RT_FLAG carry 539 
CD8_FLAG as an irrelevant tagged protein control. c) Surface plasmon 540 
resonance analysis of purified A3G and p51 on a Biacore T-200 instrument. 541 
Association and dissociation curves of p51_FLAG to immobilized A3G_6xHis 542 
at the indicated concentrations are shown. The sensorgram indicates specific 543 
binding between the two components, and the responses gave good fits to a 544 
single interaction binding model with a Kd of ~1.6 μM. d)-f) Measurements of 545 
FRET efficiency using FLIM in HeLa cells expressing GFP and mCherry 546 
fusion proteins. Representative images with GFP fluorescence from 547 
multiphoton laser scanning microscopy (left panel) and corresponding wide 548 
field CCD camera images of mCherry fluorescence (right panels (e only)) are 549 
shown. The center panels represent pseudo-colored images of GFP lifetime 550 
(τ) (blue/green, normal/longer GFP lifetime; yellow/red, shorter GFP lifetime 551 
indicating FRET).  d) Control images demonstrating normal GFP lifetime in 552 
the absence of mCherry acceptor. White scale bars represent 10 μm. e) Co-553 
expression of indicated GFP and mCherry fusion proteins and the 554 
fluorescence lifetime according to the scale in d) indicating the presence or 555 
absence of FRET. f) Dot plot of FRET efficiencies with their mean and 556 
standard deviation from n=7 cells each. 557 
 558 
  559 
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Figure 4: A3G interaction with HIV-1 RT in virions 560 
Suspensions of HIV-1 virions with packaged A3G_GFP, GFP_Vpr, 561 
GFP_CYPA or A3G_GFP and A3G_mCherry were immobilized on coverslips, 562 
fixed and stained with Cy3 labeled anti-RT or anti-CA Fab fragments. a) and 563 
b) Representative images show clusters of HIV-1 virions immobilized on 564 
fibronectin streaks with green fluorescence (left panel), red fluorescence (Cy3 565 
or mCherry as indicated, right panel) and GFP lifetime as pseudo-colored 566 
images according to the indicated scale (as in Figure 3). White scale bars 567 
represent 10 μm. a) A3G_GFP demonstrates normal lifetime when packaged 568 
into HIV-1 virions. b) FRET is detected for the positive control of A3G_GFP 569 
and A3G_mCherry (upper left panel) and between A3G_GFP and Cy3 stained 570 
RT (lower right panel), but not between Vpr and RT, CYPA and RT, or A3G 571 
and CA (upper right panels). The absence of a signal for red fluorescence 572 
with HIV-1∆RT virions confirmed the specificity of the anti-RT Fab fragments 573 
(lower left panel). c) Quantification of FRET efficiencies for n=5 areas. 574 
Individual measurements with their mean and standard deviation are shown. 575 
 576 
  577 
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Figure 5: Mapping of A3G-RT interaction sites on A3G protein 578 
a) Anti FLAG immunoprecipitation of p51_FLAG and p66_FLAG co-expressed 579 
with GST or GST_A3G fusion proteins, recovered proteins were detected with 580 
anti-GST (for A3G) or anti-FLAG antibodies as indicated. A3G truncations are 581 
indicated and numbers refer to amino acid positions in A3G. b) Co-582 
immunoprecipitation analysis of wild type or mutant A3G with HIV-1 583 
p51_FLAG and p66_FLAG, recovered proteins were detected with anti-HA 584 
(for A3G) or anti-FLAG antibodies. One representative out of three 585 
experiments is shown. c) FRET-FLIM analysis of wild type or mutant A3G with 586 
the p66 subunit of HIV-1 RT. Representative images show green fluorescence 587 
(GFP, left panel) and red fluorescence (mCherry, right panel) and GFP 588 
lifetime as pseudo-colored images according to the indicated scale (as in Fig 589 
5). White scale bars represent 10 μm. d) Dot plots showing individual FRET 590 
efficiencies with their mean and one standard deviation from n=12 cells each. 591 
*** indicates p-value of <0.0001 in an unpaired, two-tailed t-test performed in 592 
GraphPad Prism®. 593 
 594 
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Figure 6: Phenotypes of packaged L35A and R24A A3G mutant proteins 596 
on viral infectivity and cDNA profiles 597 
a) Immunoblot analysis of HIV-1 virions showing relative amounts of 598 
packaged wild type or mutant A3G_HA at constant CA levels. Ratios refer to 599 
the amounts of transfected A3G expression plasmid to proviral plasmid during 600 
virus production. b) A3G-L35A, but not A3G-R24A, displays diminished HIV-1 601 
inhibitory activity. A3G packaging was quantified by immunoblot density 602 
measurements and the different wild type A3G packaging levels were plotted 603 
over measured infectivity. The extent of infection inhibition exerted by the wild 604 
type protein at the empirically determined level of packaged mutant protein 605 
was then extrapolated (see Supplementary Fig 10). Inhibition levels, in % 606 
relative to the no A3G control, of wild type A3G (triangles) and L35A or R24A 607 
(circles) in eight (L35A) or seven (R24A) independent experiments are shown. 608 
A paired, two tailed student t test was performed in GraphPad Prism® and * 609 
indicates p<0.05 (p=0.0223), ns: not significant c) As in b), but with (-)sss 610 
cDNA abundance measured by qPCR in cells 4 h post-infection for virions 611 
carrying wild type or mutant A3G. ** indicates p<0.005 (p=0.0028). d) Relative 612 
infectivity of n=5 independent virus preparations carrying the indicated wild 613 
type or mutant A3G at equal, ‘high’ levels as shown in the representative 614 
immunoblot in Supplementary Fig 10g. A paired, two tailed student t test was 615 
performed in GraphPad Prism®. * indicates p<0.05 (p=0.0397 for A3G wt – 616 
L35A; p=0.0297 for C288S – C288S/L35A and p=0.0137 for L35A – 617 
C288S/L35A). e) Sequencing reads from a MiSeq™ library run were analyzed 618 
and presented as in Fig 1g. Labels to the right indicate the presence or 619 
absence of A3G proteins in virions. 620 
  621 
 24
References: 622 
 623 
1. Doyle, T., Goujon, C. & Malim, M.H. HIV-1 and interferons: who's 624 
interfering with whom? Nat Rev Microbiol 13, 403-13 (2015). 625 
2. Simon, V., Bloch, N. & Landau, N.R. Intrinsic host restrictions to HIV-1 626 
and mechanisms of viral escape. Nat Immunol 16, 546-53 (2015). 627 
3. Desimmie, B.A. et al. Multiple APOBEC3 restriction factors for HIV-1 628 
and one Vif to rule them all. J Mol Biol 426, 1220-45 (2014). 629 
4. Harris, R.S. & Dudley, J.P. APOBECs and virus restriction. Virology 630 
479-480, 131-45 (2015). 631 
5. Bishop, K.N. et al. Cytidine deamination of retroviral DNA by diverse 632 
APOBEC proteins. Curr Biol 14, 1392-6 (2004). 633 
6. Hultquist, J.F. et al. Human and rhesus APOBEC3D, APOBEC3F, 634 
APOBEC3G, and APOBEC3H demonstrate a conserved capacity to 635 
restrict Vif-deficient HIV-1. J Virol 85, 11220-34 (2011). 636 
7. Sheehy, A.M., Gaddis, N.C., Choi, J.D. & Malim, M.H. Isolation of a 637 
human gene that inhibits HIV-1 infection and is suppressed by the viral 638 
Vif protein. Nature 418, 646-50 (2002). 639 
8. Apolonia, L. et al. Promiscuous RNA binding ensures effective 640 
encapsidation of APOBEC3 proteins by HIV-1. PLoS Pathog 11, 641 
e1004609 (2015). 642 
9. Luo, K. et al. Amino-terminal region of the human immunodeficiency 643 
virus type 1 nucleocapsid is required for human APOBEC3G 644 
packaging. J Virol 78, 11841-52 (2004). 645 
10. Soros, V.B., Yonemoto, W. & Greene, W.C. Newly synthesized 646 
APOBEC3G is incorporated into HIV virions, inhibited by HIV RNA, and 647 
subsequently activated by RNase H. PLoS Pathog 3, e15 (2007). 648 
11. Sheehy, A.M., Gaddis, N.C. & Malim, M.H. The antiretroviral enzyme 649 
APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. 650 
Nat Med 9, 1404-7 (2003). 651 
12. Marin, M., Rose, K.M., Kozak, S.L. & Kabat, D. HIV-1 Vif protein binds 652 
the editing enzyme APOBEC3G and induces its degradation. Nat Med 653 
9, 1398-403 (2003). 654 
13. Yu, X. et al. Induction of APOBEC3G ubiquitination and degradation by 655 
an HIV-1 Vif-Cul5-SCF complex. Science 302, 1056-60 (2003). 656 
14. Gillick, K. et al. Suppression of HIV-1 infection by APOBEC3 proteins 657 
in primary human CD4(+) T cells is associated with inhibition of 658 
processive reverse transcription as well as excessive cytidine 659 
deamination. J Virol 87, 1508-17 (2013). 660 
15. Phalora, P.K., Sherer, N.M., Wolinsky, S.M., Swanson, C.M. & Malim, 661 
M.H. HIV-1 replication and APOBEC3 antiviral activity are not 662 
regulated by P bodies. J Virol 86, 11712-24 (2012). 663 
16. Harris, R.S. et al. DNA deamination mediates innate immunity to 664 
retroviral infection. Cell 113, 803-9 (2003). 665 
17. Mangeat, B. et al. Broad antiretroviral defence by human APOBEC3G 666 
through lethal editing of nascent reverse transcripts. Nature 424, 99-667 
103 (2003). 668 
 25
18. Zhang, H. et al. The cytidine deaminase CEM15 induces 669 
hypermutation in newly synthesized HIV-1 DNA. Nature 424, 94-8 670 
(2003). 671 
19. Bishop, K.N., Holmes, R.K. & Malim, M.H. Antiviral potency of 672 
APOBEC proteins does not correlate with cytidine deamination. J Virol 673 
80, 8450-8 (2006). 674 
20. Bishop, K.N., Verma, M., Kim, E.Y., Wolinsky, S.M. & Malim, M.H. 675 
APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS 676 
Pathog 4, e1000231 (2008). 677 
21. Holmes, R.K., Koning, F.A., Bishop, K.N. & Malim, M.H. APOBEC3F 678 
can inhibit the accumulation of HIV-1 reverse transcription products in 679 
the absence of hypermutation. Comparisons with APOBEC3G. J Biol 680 
Chem 282, 2587-95 (2007). 681 
22. Iwatani, Y. et al. Deaminase-independent inhibition of HIV-1 reverse 682 
transcription by APOBEC3G. Nucleic Acids Res 35, 7096-108 (2007). 683 
23. Schrofelbauer, B., Yu, Q., Zeitlin, S.G. & Landau, N.R. Human 684 
immunodeficiency virus type 1 Vpr induces the degradation of the UNG 685 
and SMUG uracil-DNA glycosylases. J Virol 79, 10978-87 (2005). 686 
24. Yang, B., Chen, K., Zhang, C., Huang, S. & Zhang, H. Virion-687 
associated uracil DNA glycosylase-2 and apurinic/apyrimidinic 688 
endonuclease are involved in the degradation of APOBEC3G-edited 689 
nascent HIV-1 DNA. J Biol Chem 282, 11667-75 (2007). 690 
25. Kaiser, S.M. & Emerman, M. Uracil DNA glycosylase is dispensable for 691 
human immunodeficiency virus type 1 replication and does not 692 
contribute to the antiviral effects of the cytidine deaminase Apobec3G. 693 
J Virol 80, 875-82 (2006). 694 
26. Langlois, M.A. & Neuberger, M.S. Human APOBEC3G can restrict 695 
retroviral infection in avian cells and acts independently of both UNG 696 
and SMUG1. J Virol 82, 4660-4 (2008). 697 
27. Mbisa, J.L. et al. Human immunodeficiency virus type 1 cDNAs 698 
produced in the presence of APOBEC3G exhibit defects in plus-strand 699 
DNA transfer and integration. J Virol 81, 7099-110 (2007). 700 
28. Newman, E.N. et al. Antiviral function of APOBEC3G can be 701 
dissociated from cytidine deaminase activity. Curr Biol 15, 166-70 702 
(2005). 703 
29. Mbisa, J.L., Bu, W. & Pathak, V.K. APOBEC3F and APOBEC3G inhibit 704 
HIV-1 DNA integration by different mechanisms. J Virol 84, 5250-9 705 
(2010). 706 
30. Chaurasiya, K.R. et al. Oligomerization transforms human APOBEC3G 707 
from an efficient enzyme to a slowly dissociating nucleic acid-binding 708 
protein. Nat Chem 6, 28-33 (2014). 709 
31. Wang, X. et al. The cellular antiviral protein APOBEC3G interacts with 710 
HIV-1 reverse transcriptase and inhibits its function during viral 711 
replication. J Virol (2012). 712 
32. Hu, W.S. & Hughes, S.H. HIV-1 reverse transcription. Cold Spring Harb 713 
Perspect Med 2(2012). 714 
33. Herschhorn, A. & Hizi, A. Retroviral reverse transcriptases. Cell Mol 715 
Life Sci 67, 2717-47 (2010). 716 
34. Gillick, K. et al. The suppression of HIV-1 infection by APOBEC3 717 
proteins in primary human CD4+ T cells is associated with the 718 
 26
inhibition of processive reverse transcription as well as excessive 719 
cytidine deamination submitted to J Virol (2012). 720 
35. Arts, E.J., Li, Z. & Wainberg, M.A. Analysis of Primer Extension and the 721 
First Template Switch during Human Immunodeficiency Virus Reverse 722 
Transcription. J Biomed Sci 2, 314-321 (1995). 723 
36. Driscoll, M.D., Golinelli, M.P. & Hughes, S.H. In vitro analysis of human 724 
immunodeficiency virus type 1 minus-strand strong-stop DNA synthesis 725 
and genomic RNA processing. J Virol 75, 672-86 (2001). 726 
37. Harrison, G.P., Mayo, M.S., Hunter, E. & Lever, A.M. Pausing of 727 
reverse transcriptase on retroviral RNA templates is influenced by 728 
secondary structures both 5' and 3' of the catalytic site. Nucleic Acids 729 
Res 26, 3433-42 (1998). 730 
38. Kim, E.Y. et al. Human APOBEC3 Induced Mutation of Human 731 
Immunodeficiency Virus Type-1 Contributes to Adaptation and 732 
Evolution in Natural Infection. PLoS Pathog 10, e1004281 (2014). 733 
39. Yu, Q. et al. Single-strand specificity of APOBEC3G accounts for 734 
minus-strand deamination of the HIV genome. Nat Struct Mol Biol 11, 735 
435-42 (2004). 736 
40. Schormann, N., Ricciardi, R. & Chattopadhyay, D. Uracil-DNA 737 
glycosylases-structural and functional perspectives on an essential 738 
family of DNA repair enzymes. Protein Sci 23, 1667-85 (2014). 739 
41. Visnes, T. et al. Uracil in DNA and its processing by different DNA 740 
glycosylases. Philos Trans R Soc Lond B Biol Sci 364, 563-8 (2009). 741 
42. Wang, Z. & Mosbaugh, D.W. Uracil-DNA glycosylase inhibitor gene of 742 
bacteriophage PBS2 encodes a binding protein specific for uracil-DNA 743 
glycosylase. J Biol Chem 264, 1163-71 (1989). 744 
43. Mansky, L.M., Preveral, S., Selig, L., Benarous, R. & Benichou, S. The 745 
interaction of vpr with uracil DNA glycosylase modulates the human 746 
immunodeficiency virus type 1 In vivo mutation rate. J Virol 74, 7039-747 
47 (2000). 748 
44. Willetts, K.E. et al. DNA repair enzyme uracil DNA glycosylase is 749 
specifically incorporated into human immunodeficiency virus type 1 750 
viral particles through a Vpr-independent mechanism. J Virol 73, 1682-751 
8 (1999). 752 
45. Adolph, M.B., Webb, J. & Chelico, L. Retroviral restriction factor 753 
APOBEC3G delays the initiation of DNA synthesis by HIV-1 reverse 754 
transcriptase. PLoS One 8, e64196 (2013). 755 
46. Voss, T.C., Demarco, I.A. & Day, R.N. Quantitative imaging of protein 756 
interactions in the cell nucleus. Biotechniques 38, 413-24 (2005). 757 
47. Burnett, A. & Spearman, P. APOBEC3G multimers are recruited to the 758 
plasma membrane for packaging into human immunodeficiency virus 759 
type 1 virus-like particles in an RNA-dependent process requiring the 760 
NC basic linker. J Virol 81, 5000-13 (2007). 761 
48. Wiegand, H.L., Doehle, B.P., Bogerd, H.P. & Cullen, B.R. A second 762 
human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 763 
and HIV-2 Vif proteins. EMBO J 23, 2451-8 (2004). 764 
49. Wedekind, J.E. et al. Nanostructures of APOBEC3G support a 765 
hierarchical assembly model of high molecular mass ribonucleoprotein 766 
particles from dimeric subunits. J Biol Chem 281, 38122-6 (2006). 767 
 27
50. Gallois-Montbrun, S. et al. Comparison of cellular ribonucleoprotein 768 
complexes associated with the APOBEC3F and APOBEC3G antiviral 769 
proteins. J Virol 82, 5636-42 (2008). 770 
51. Huthoff, H., Autore, F., Gallois-Montbrun, S., Fraternali, F. & Malim, 771 
M.H. RNA-dependent oligomerization of APOBEC3G is required for 772 
restriction of HIV-1. PLoS Pathog 5, e1000330 (2009). 773 
52. Xiao, X., Li, S.X., Yang, H. & Chen, X.S. Crystal structures of 774 
APOBEC3G N-domain alone and its complex with DNA. Nat Commun 775 
7, 12193 (2016). 776 
53. Menendez-Arias, L., Sebastian-Martin, A. & Alvarez, M. Viral reverse 777 
transcriptases. Virus Res (2016). 778 
54. Levin, J.G., Mitra, M., Mascarenhas, A. & Musier-Forsyth, K. Role of 779 
HIV-1 nucleocapsid protein in HIV-1 reverse transcription. RNA Biol 7, 780 
754-74 (2010). 781 
55. Basu, V.P. et al. Strand transfer events during HIV-1 reverse 782 
transcription. Virus Res 134, 19-38 (2008). 783 
56. Iwatani, Y., Rosen, A.E., Guo, J., Musier-Forsyth, K. & Levin, J.G. 784 
Efficient initiation of HIV-1 reverse transcription in vitro. Requirement 785 
for RNA sequences downstream of the primer binding site abrogated 786 
by nucleocapsid protein-dependent primer-template interactions. J Biol 787 
Chem 278, 14185-95 (2003). 788 
57. Masuda, T. et al. Fate of HIV-1 cDNA intermediates during reverse 789 
transcription is dictated by transcription initiation site of virus genomic 790 
RNA. Sci Rep 5, 17680 (2015). 791 
58. Kharytonchyk, S. et al. Transcriptional start site heterogeneity 792 
modulates the structure and function of the HIV-1 genome. Proc Natl 793 
Acad Sci U S A 113, 13378-13383 (2016). 794 
59. Klarmann, G.J., Schauber, C.A. & Preston, B.D. Template-directed 795 
pausing of DNA synthesis by HIV-1 reverse transcriptase during 796 
polymerization of HIV-1 sequences in vitro. J Biol Chem 268, 9793-802 797 
(1993). 798 
60. Altfeld, M. & Gale, M., Jr. Innate immunity against HIV-1 infection. Nat 799 
Immunol 16, 554-62 (2015). 800 
61. Ahn, J. et al. HIV-1 Vpr loads uracil DNA glycosylase-2 onto DCAF1, a 801 
substrate recognition subunit of a cullin 4A-ring E3 ubiquitin ligase for 802 
proteasome-dependent degradation. J Biol Chem 285, 37333-41 803 
(2010). 804 
62. Steagall, W.K., Robek, M.D., Perry, S.T., Fuller, F.J. & Payne, S.L. 805 
Incorporation of uracil into viral DNA correlates with reduced replication 806 
of EIAV in macrophages. Virology 210, 302-13 (1995). 807 
63. Kennedy, E.M. et al. Abundant non-canonical dUTP found in primary 808 
human macrophages drives its frequent incorporation by HIV-1 reverse 809 
transcriptase. J Biol Chem 286, 25047-55 (2011). 810 
64. Yan, N., O'Day, E., Wheeler, L.A., Engelman, A. & Lieberman, J. HIV 811 
DNA is heavily uracilated, which protects it from autointegration. Proc 812 
Natl Acad Sci U S A 108, 9244-9 (2011). 813 
65. Hansen, E.C. et al. Diverse fates of uracilated HIV-1 DNA during 814 
infection of myeloid lineage cells. Elife 5(2016). 815 
 28
66. Weil, A.F. et al. Uracil DNA glycosylase initiates degradation of HIV-1 816 
cDNA containing misincorporated dUTP and prevents viral integration. 817 
Proc Natl Acad Sci U S A 110, E448-57 (2013). 818 
67. Chen, R., Wang, H. & Mansky, L.M. Roles of uracil-DNA glycosylase 819 
and dUTPase in virus replication. J Gen Virol 83, 2339-45 (2002). 820 
68. Sire, J., Querat, G., Esnault, C. & Priet, S. Uracil within DNA: an actor 821 
of antiviral immunity. Retrovirology 5, 45 (2008). 822 
69. Stremlau, M. et al. The cytoplasmic body component TRIM5alpha 823 
restricts HIV-1 infection in Old World monkeys. Nature 427, 848-53 824 
(2004). 825 
70. Stremlau, M. et al. Specific recognition and accelerated uncoating of 826 
retroviral capsids by the TRIM5alpha restriction factor. Proc Natl Acad 827 
Sci U S A 103, 5514-9 (2006). 828 
71. Malim, M.H. & Bieniasz, P.D. HIV Restriction Factors and Mechanisms 829 
of Evasion. Cold Spring Harb Perspect Med 2, a006940 (2012). 830 
72. Warren, K., Warrilow, D., Meredith, L. & Harrich, D. Reverse 831 
Transcriptase and Cellular Factors: Regulators of HIV-1 Reverse 832 
Transcription. Viruses 1, 873-94 (2009). 833 
73. Salter, J.D., Bennett, R.P. & Smith, H.C. The APOBEC Protein Family: 834 
United by Structure, Divergent in Function. Trends Biochem Sci 41, 835 
578-94 (2016). 836 
 837 
 1
Online Methods 1 
 2 
Plasmid constructs 3 
The expression vector for Vif-deficient HIV-1NL4.3 has been described 4 
previously1. Wild type and mutant A3G proteins carrying the carboxy-terminal 5 
3xHA tag were expressed using pCMV4_HA2,3. Site-directed mutagenesis 6 
was carried out based on the QuikChange protocol (Stratagene) using Pfu 7 
polymerase (Stratagene). Transfer plasmids for the generation of recombinant 8 
baculovirus were generated as follows: wild type or mutant A3G sequences 9 
were PCR amplified and cloned into pCGTHCFFLT7 with a carboxy-terminal 10 
6xHis tag sequence using XbaI and AgeI restriction sites. The tagged A3G 11 
insert was subsequently PCR amplified and inserted into the pVL1392 12 
transfer vector (BD Biosciences) using EcoRI and XmaI restriction sites. 13 
Expression vectors for HIV-1 RT p51 and p66 were created as follows: a 14 
codon optimized gag-pol plasmid (pCO Gag-pol,4) was used as the PCR 15 
template, and. fragments were subcloned into pCAGGS using XmaI/NotI 16 
(p51) or EcoRI/XmaI (p66). The reverse primers were designed with or 17 
without a 1xFLAG tag coding sequence. Expression vectors encoding 18 
truncated A3G proteins with amino-terminal GST tags were generated by 19 
PCR amplification and subcloned into pCAGGS_GST with EcoRI/XhoI. 20 
Fluorescent protein fusions were expressed from plasmid constructs carrying 21 
the respective cDNA sequence from the aforementioned vectors and 22 
subcloned in pEGFP_N1 (Clontech) and pmCherry_N1 (Clontech) vectors. 23 
The cDNA for the (human) codon optimized uracil-DNA glycosylase inhibitor 24 
(hUGI) gene was a gift from Michael Emerman5 and was subcloned into the 25 
MLV-based transfer vector pCMS286. MLV packaging and VSV-G expression 26 
vectors have been described7.  27 
 28 
Cell lines and stable cell lines 29 
HEK293T and HeLa cells were obtained from ATCC. TZM-bl cells were 30 
obtained through the NIH AIDS Reagents Repository Program (ARRP). Cells 31 
were cultured in Dulbecco’s modified Eagle’s medium (Invitrogen, UK) 32 
supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. 33 
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CEM-SS cells, also from ARRP, were cultured in Roswell Park Memorial 34 
Institute (RPMI) 1640 medium (Invitrogen, UK) supplemented with 10% fetal 35 
bovine serum and 1% penicillin/streptomycin. All cells were tested and found 36 
to be negative for mycoplasma contamination. hUGI expressing HEK293T, 37 
CEM-SS and TZM-bl cells were created using standard MLV-based 38 
transduction vectors. HEK293T cells were co-transfected with expression 39 
plasmids for VSV-G, an MLV packaging plasmid and pCMS28 encoding 40 
hUGI. Transduced cells were selected with  1μg/ml puromycin.  41 
 42 
Virion production 43 
HEK293T cells were seeded in 10 cm tissue culture plates and co-transfected 44 
with 10 μg pNL4.3/∆Vif and 0.25 to 10 μg pCMV4_A3G_HA wild type or 45 
mutant expression vectors using polyethylenimine (PEI, Molecular 46 
Biosciences). Total DNA levels were kept constant with empty pCMV4-HA 47 
vector. At 48 h, supernatants were harvested, DNAse (RQ1 RNase free 48 
DNAse (Promega)) treated for 1 h at 37°C and viruses then purified through a 49 
20% (w/v) sucrose cushion at 28,000 x g for 75 min at 4°C. Viruses were 50 
resuspended in PBS, and quantified according to p24Gag content using an 51 
enzyme-linked immunosorbent assay (ELISA; Perkin-Elmer). 52 
 53 
TZM-bl reporter assay 54 
TZM-bl reporter assays were utilized to measure single cycle HIV-1 infectivity. 55 
Virus inputs equivalent to 10 or 20 ng p24Gag were used to challenge 0.5 x 105 56 
cells in 48-well format. At 48 h post infection, whole-cell lysates were assayed 57 
for the induction of β-galactosidase expression using a Galacto-Star system 58 
(Applied Biosystems). 59 
 60 
Infections 61 
CEM-SS T cells were seeded at 1 x 106 cells per 0.5 ml of medium in a 12-62 
well format. Virus equivalent to 75 ng p24Gag was added and the cells were 63 
spin-infected at 2,000 x g for 2 h at 30°C. After centrifugation, cells were left 64 
to recover for 1 h in the incubator, before 2 washes with PBS to remove the 65 
inoculum. Cells were maintained in fresh media for 1 h before being harvested 66 
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by centrifugation, and pellets either frozen at -80°C or immediately processed 67 
for DNA extraction.  68 
 69 
DNA extraction and quantitative real time PCR 70 
Whole cell DNA was isolated using the DNAeasy Blood and Tissue Kit 71 
(Qiagen) according to the manufacturer’s protocol. DNA was eluted with 200 72 
μl H2O. 17.5 μl were mixed with 2 μl Cutsmart buffer (NEB) and 0.5 μl DnpI 73 
(NEB) (to eliminate any remaining transfected plasmid) for 1 h at 37°C before 74 
analysis by quantitative PCR. The remaining nucleic acid fraction was 75 
reserved for library preparation. Early reverse transcription products were 76 
detected using primers that amplify the region between nucleotides 500 and 77 
635 of the provirus: oHC64 (5’-taactagggaacccactgc-3’) and oHC65 (5’-78 
gctagagattttccacactg-3’) and probe oHC66 (5’-FAM-79 
acacaacagacgggcacacacta-TAMRA-3’). Reactions were performed in 80 
duplicate, in TaqMan Universal PCR master mix (no AmpErase), using 0.9 81 
pmol of each primer per μl and 0.25 pmol probe per μl. After 10 min at 95°C, 82 
reactions were cycled through 15 s at 95°C, followed by 1 min at 60°C for 40 83 
repeats, carried out on an ABI Prism model 7900HT (Applied Biosystems).  84 
pNL4.3/∆Vif, was diluted in herring sperm DNA to generate a standard curve. 85 
 86 
Statistical analysis 87 
Where indicated a paired or unpaired, two-tailed t-test was carried out using 88 
the t-test function in GraphPad Prism® 6.0.  89 
 90 
MiSeq library preparation 91 
Enrichment for HIV-1 specific sequences 92 
Whole cell DNA from infected cells was isolated as above and HIV-1 specific 93 
DNA was enriched over the genomic DNA. Biotinylated oligonucleotides 94 
complementary to the HIV-1 sequence (within the tRNA primer and within the 95 
first 22 nt of the strong stop sequence, see exact sequences below) were 96 
annealed to the cDNA sample and a pulldown with magnetic strepdavidin 97 
beads was performed: for each sample, 100 μl strepdavidin beads (Promega, 98 
Magnasphere (Z5481) were washed (using a magnet) with 100 μl of bind and 99 
wash buffer (BW: 5 mM Tris pH 7.5, 0.5 mM EDTA, 1 M NaCl) then blocked 100 
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for 10 min in casein solution at room temperature, and again washed once in 101 
BW buffer. Beads were resuspended in BW buffer containing 50 pmol 5'-102 
cagtgtggaaaatctctagcag-biotin-3’, 5'-cagtggcgcccgaaca-biotin-3’, and 5'-biotin-103 
cagtgtggaaaatctctagcagtggcgcccgaacagggac-biotin-3’. The mixture was left 104 
for 30 min at room temperature while rotating. Beads were then washed twice 105 
in 1xTEN buffer (10 mM Tris HCl pH 8.0, 1 mM EDTA, 100 mM NaCl) and 106 
then resuspended in 10 μl TEN buffer. This was added to 170 μl DNA and 90 107 
μl 3xTEN. Samples were denatured at 92°C for 2 min and incubated at 52°C 108 
for 1 h. Finally, beads were washed once with 1xTEN buffer and resuspended 109 
in 50 μl H2O. To elute the DNA, samples were heated to 92°C for 2 min, put 110 
on the magnet and the supernatant removed quickly.  111 
 112 
Adaptor ligation 113 
The barcoded adaptor carries a 5’ phosphate group (PHO) and a 3’ three 114 
carbon chain (C3) spacer (SpC3) on to the 3’ hydroxyl group (5’-PHO-115 
tgaagagcctagtcgctgttcannnnnnctgcccatagagagatcggaagagcacacgtct-SpC3-3’) 116 
(Integrated DNA Technologies or MWG Eurofins) and was self annealed in T4 117 
DNA ligase buffer by heating to 92°C followed by slow cooling to 16°C (2% 118 
slope on Eppendorf PCR machine). Ligation reactions were set up in 60 μl 119 
total volume, with 6 μl T4 DNA ligase buffer, 24 μl 50% PEG-8000 (Sigma), 6 120 
μl 5 M betaine (Sigma), 4 μl pre-annealed adaptor (400 pmol total), 1.2 μl T4 121 
DNA ligase (NEB, 2,000,000 units/ml) and 18.8 μl DNA sample.  Reactions 122 
were incubated at 16°C overnight. As controls, instead of DNA samples, HTP 123 
control oligos (listed in Supplemental Figure 2) at 100 pmol/μl were mixed at 124 
equimolar ratios and then diluted 1 in 62,500 before being ligated as above.  125 
 126 
Adaptor removal and size selection 127 
Ligations were denatured by adding 30 μl gel loading buffer II (Ambion, 128 
formamide buffer) and heating for 2 min at 94°C before being put on ice. 6% 129 
TBE urea gels (precast, Life Technologies) were prerun in 1xTBE buffer for 130 
~15 min at 250 V, and each sample was loaded into three adjacent wells. 131 
Gels were run for 20 min at 250 V before gel strips containing samples were 132 
immersed in 1xTBE and SYBR Gold (Thermo Fisher). To avoid cross-133 
contamination between samples during staining and gel cutting, a maximum 134 
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of two samples were run per gel and gels were cut for separate staining. After 135 
5 min, DNA was visualized on a visible blue light LED transilluminator (Dark 136 
Reader, Clare Chemicals), gels were cut right above the adaptor and the 137 
smear between the adaptor and the well was divided into three even pieces. 138 
Each piece was crushed and 1 ml urea gel extraction buffer (0.5 M 139 
NH4CH3CO2, 1 mM EDTA, 0.2% SDS) was added. Tubes were rotated for 3 140 
to 5 h and the suspensions were transferred into SpinX columns (0.2 μm, 141 
Acetate; Corning Costar) with a round whatman filter to prevent membrane 142 
clogging. Columns were centrifuged at 14 000 x g for 1 min. The elutions were 143 
combined with 3 μg polyA carrier RNA, 1 μl glycogen, and 0.7 ml isopropanol. 144 
Samples were frozen overnight, centrifuged for 30 min at 14 000 x g and DNA 145 
pellets were washed with 80% EtOH. Any remaining EtOH was evaporated at 146 
55°C. Dried pellets were resuspended in 20 μl H2O.  147 
 148 
PCR and preparation for MiSeq™ run 149 
PCR reactions contained 20 μl Accuprime Supermix I (Invitrogen), 18 μl DNA, 150 
1 μl of 10 μM MP1.0+22HIV, a sequence modified multiplexing PCR primer 151 
1.0 (MP1.0 (Illumina)) (5’-aatgatacggcgaccaccgagatctacactctttccctacacgacgct 152 
cttccgatctcactgctagagattttccacactg-3’) from MWG Eurofins and 1 μl NEB 153 
index primer (NEBNext for Illumina Multiplex Oligo Kit). For each of the three 154 
gel pieces from the same sample, separate PCR reactions, but the same 155 
index primer was used. A 25 cycle PCR was performed at 55°C annealing 156 
and 68°C extension. Half of each PCR reaction was pooled together and 157 
purified with AmpureXP beads (1.8x ratio) according to the manufacturer’s 158 
instructions. Concentrations were determined using a Qubit Fluorometer 159 
(Invitrogen) and the size range was determined by Tapestation (Agilent) 160 
measurements. Typical tapestation gel images showed material to be 161 
between roughly 150 bp to 500 bp long with two wide peaks at about 160 bp 162 
and 350 bp. On initial library preparation optimization, TopoTA cloning and 163 
individual sequencing of 10 or more colonies was performed to check inserts. 164 
The final library concentration was adjusted to 4 nM.  165 
 166 
MiSeq™ library runs and data analysis 167 
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Libraries were run on an Illumina MiSeq™ Benchtop Sequencer using the 168 
MiSeq™ Reagent Kit v3 (150 cycle) and the ‘Generate FASTQ’ workflow at 169 
University College London (UCL) Institute for Neurology Next Generation 170 
Sequencing Facility or at the King’s College London Genomics Centre.  Read 171 
lengths were set at 26 bases for Read1 and 142 or 125 bases for Read2. The 172 
two libraries from which data are shown in this article had passfilter 173 
percentages (PF%) of 93.68% and 93.11% with quality scores (AVG % Q30) 174 
of 89.05% and 82.45%, respectively.  175 
 176 
The main information extracted from each read were: first, the last nucleotide 177 
of the HIV-1 sequence adjacent to the fixed adaptor sequence, which was 178 
ligated to the viral cDNAs (see Figure 1c and Supplementary Figure 1b). This 179 
represents the open 3’-terminus of the viral cDNA at time of harvest and, 180 
second, the base variation of all bases, in particular C to T mutations. For this 181 
purpose FASTQ files were subjected to in house analysis. Adaptors were 182 
trimmed and sequences that were duplicated (including the barcode) were 183 
removed as PCR artifacts. The remaining sequences were aligned to the HIV-184 
1 sequence using Bowtie (http://bowtie-bio.sourceforge.net/index.shtml), 185 
allowing a maximum of 3 base mismatches, and the position of 3’-termini for 186 
each read was determined from the alignment position. Mutation rates from 187 
the template sequence for each base were also calculated. Where required, a 188 
linear length-dependent correction factor was calculated from synthesized 189 
oligos control library (see Supplementary Figure 2) and applied to the dataset 190 
to correct for differences in sequencing efficiency of longer products.  191 
 192 
Output files for each indexed sample were designed to yield the number of 193 
total unique reads for each nucleotide position in the (-)sss product of the HIV-194 
1NL4.3 proviral sequence. The template that was used spanned the strong stop 195 
and first strand transfer sequences up to the polypurine tract (U5-R-U3-PPT; 196 
635 bases total). Of note, only sequences of a minimal length of 22 nt are 197 
accounted for in this library due to primer design. Accordingly, there were 613 198 
possible termini for the cDNA sequences in total, though our main analysis 199 
focuses on the 160 nt up to base 182, the strong stop site. For base 200 
substitution analysis, parse results presented the number of each of the four 201 
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possible base calls for each nucleotide position. Percentages could therefore 202 
be calculated from the total coverage of each base. Notably, coverage for 203 
each base itself is not constant for two reasons: one, the 3’-termini of 204 
individual reads vary, thereby coverage ends at varying sites; and, two, 205 
Read2 sequence length of 142 or 125 (depending on the library) may not 206 
reach the 5’ end of strong stop, depending on the starting position. 207 
 208 
Relative abundance of cDNA along the (-)sss sequence in the main figures 209 
was calculated by dividing the number of total reads for each nt position by 210 
the number of total reads up to nt 182 (for total reads see Supplementary Fig 211 
4b). The sole exception is Supplementary Figure 4a, which shows profiles 212 
beyond first strand transfer, where the read number was divided by the total 213 
read count in the entire sample. All figures displaying cDNA profiles (Fig 1g, 214 
2d, 6e, and Supplementary Fig 2a, 4a, 5 and 7) show the relative abundance 215 
of HIV-1 cDNA molecules for each length between nt positions 23 and 182 of 216 
the HIV-1NL4.3 (-)sss product (in blue histogram bars, scale on the left y-axis). 217 
All positions with cytosine bases in the HIV-1NL4.3 (-)sss sequence were 218 
analyzed for the presence of cytosine versus thymine/uracil bases as 219 
described above; shown in dashed red lines is the percentage of reads, which 220 
carried C to T/U mutations at the indicated position (scale on the right y-axis). 221 
Labels to the right of the graphs describe the virions used for infection.  222 
 223 
Data and code availability 224 
The data supporting this study and custom software are available from the 225 
corresponding author upon reasonable request. There are no restrictions to 226 
data availability. Raw MiSeq® sequencing files analyzed in this study 227 
(presented in Fig 1g, 2d, 6e as well as Supplementary Fig 2, 4, 5 and 7) are 228 
also publicly available at the European Nucleotide Archive (ENA) under study 229 
accession number PRJEB22170. Individual accession codes for each sample 230 
are listed in Supplementary Figure 4b. Custom computer code used to 231 
analyze the raw MiSeq® reads is deposited in GitHub and publicly available 232 
(doi:10.5281/zenodo.1004571).  233 
 234 
Co-immunoprecipitation assays 235 
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HEK293T cells were transfected in 6 well format using PEI. At 36 h, cells were 236 
scraped in ice-cold PBS, pelleted (2 min, 500 x g) and lysed in DMEM (Gibco) 237 
+ 0.5% IGEPAL CA 630 (Sigma) plus protease inhibitor cocktail (Roche). 238 
After 10 min on ice, cell lysates were sonicated for 10 s, and clarified by 239 
centrifugation at 1000 x g for 10 min. Magnetic protein G Dynabeads 240 
(Invitrogen) were washed twice in PBS using a magnetic stand and then pre-241 
incubated with FLAG_M2 antibody (Sigma). The charged magnetic beads 242 
were washed once, distributed to the different cell lysates and rocked at 4°C 243 
for 2 h. Beads were washed four times with DMEM + 0.5% IGEPAL CA 630 244 
and proteins then eluted with protein loading buffer (according to Laemmli), 245 
resolved by SDS PAGE and analyzed by standard immunoblot analysis. 246 
Antibodies used include anti-HA-HRP (3F10, Roche), unconjugated anti-HA 247 
(3F10, Roche, )anti-FLAG M2-HRP (Sigma), anti-RT (mAb21, NIH AIDS 248 
Reagents Repository Program (ARRP)), anti-p24Gag (mouse monoclonal, 24-249 
28) and anti-GST-HRP (RPN1236, Sigma). Horseradish peroxidase-250 
conjugated primary or secondary antibodies were visualized by enhanced 251 
chemiluminescence (Pierce) and unconjugated primary antibodies were 252 
detected by infrared IRDye-conjugated secondary antibodies (LI-COR 253 
Biosciences) and LI-COR infrared imaging technology (LI-COR UK Ltd.) All 254 
blots in their un-cropped versions and including molecular weight markers are 255 
presented in Supplementary Fig 11.  256 
 257 
For co-immunoprecipitation experiments with FLAG_RT and GST_A3G 258 
truncations, 50 mM NaCl was added to DMEM + 0.5% IGEPAL CA 630 during 259 
washes for more stringency. Additionally, proteins were eluted after the 2 h 260 
incubation by competition with 3xFLAG peptide (150 μg/ml) for 30 min instead 261 
of direct elution by protein loading buffer.   262 
 263 
For co-immunoprecipitation coupled with RNase treatment, all starting 264 
materials were doubled and the reactions were carried out as above until the 265 
2 h incubation. Magnetic beads were washed twice in DMEM + 0.5% IGEPAL 266 
CA 630 and reactions were split in three parts with one part left untreated and 267 
RNaseA (Sigma) or RNase Mix (Roche) added to the two remaining reactions 268 
at concentrations up to 100 μg/ml or 20 μg/ml, respectively. All reactions were 269 
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incubated at room temperature for 30 min while rocking and then washed two 270 
more times in DMEM + 0.5% IGEPAL CA 630 before elution in protein loading 271 
buffer.  272 
 273 
Surface plasmon resonance 274 
Purification of p51 for surface plasmon resonance experiments  275 
HIV-1 p51 RT was purified from 20 10 cm dishes of HEK293T cells 276 
transfected with p51_FLAG using anti-FLAG magnetic affinity resin (Sigma). 277 
Briefly, at 48 h after transfection, cells were lysed in 50 mM Tris HCL 7.6, 150 278 
mM NaCl, 0.5% Triton, 1 mM EDTA supplemented with 50 μg/ml RNase A 279 
(Sigma) and protease inhibitor (Roche), and incubated for 10 min on ice. 280 
Lysates were sonicated, clarified by centrifugation, and incubated with anti-281 
FLAG M2 magnetic beads (Sigma) for 3 h. The beads were washed 282 
extensively with lysis buffer and eluted three times with lysis buffer containing 283 
150 μg/ml 3xFLAG peptide (Sigma). Elutions were combined and dialyzed 284 
against PBS + 0.01% IGEPAL CA 630 (Sigma) to remove the peptides.  285 
Samples were concentrated to 10 μM as determined by Bradford assay, and 286 
homogeneity was judged by Coomassie staining (see Supplemental Figure 8). 287 
 288 
Surface plasmon resonance experiments 289 
p51_FLAG was diluted to 8 μM before preparing a 2-fold dilution series down 290 
to 0.16 μM. A3G was purified as below, dialyzed against PBS + 0.01% 291 
IGEPAL CA 630 and used at a final concentration of 10 nM. Interaction 292 
analyses were performed on a Biacore T200 instrument (GE Healthcare). 293 
Binding surfaces for 6xHis tagged A3G were created by immobilizing an anti-294 
His antibody (Biacore/GE Healthcare) onto a Series S CM5 sensor chip 295 
surface (Biacore/GE Healthcare) by amine coupling. The capture of the A3G 296 
ligand was carried out at low surface density (~200 RU) to minimize potential 297 
A3G-A3G interactions and ensure monomeric interactions with p51. The p51 298 
analyte was injected at different concentrations, each in duplicate, in running 299 
buffer (PBS + 0.01% IGEPAL CA 630) at 15 μl/min for 4 min followed by a 15 300 
min dissociation time. Standard double referencing data subtraction methods 301 
were applied9.  302 
 303 
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Fluorescence resonance energy transfer (FRET) detected by 304 
fluorescence lifetime imaging microscopy (FLIM) 305 
The interaction between A3G and HIV-1 RT subunits was measured by 306 
measuring FRET between fluorescent protein tags on the respective proteins 307 
of interest. Energy transfer between fluorescent proteins quickly loses its 308 
efficiency as it decreases to the sixth power of distance and is limited to a 309 
distance of less than 10 nm. The detection of FRET suggests proximity of two 310 
fluorophores on the scale of Angstrom10. The efficiency of FRET was 311 
determined by FLIM where fluorescent lifetime refers to the period of time a 312 
fluorescent molecule stays in an excited state and emitting a photon. FRET 313 
leads to a decrease in the fluorescence lifetime of the donor molecule that can 314 
be very accurately measured using time-correlated single photon counting. 315 
Contrary to other spectral methods of measuring FRET, such as sensitized 316 
emission FRET (SE-FRET or ratiometric imaging) or acceptor photobleaching, 317 
the ability to measure the fluorescence lifetime of fluorescent proteins 318 
expressed in cells is independent of relative probe concentrations and 319 
intensities, as well as being independent of photo-bleaching and spectral 320 
bleed through11-13. FLIM is therefore a sensitive and accurate approach to 321 
measure FRET between two co-expressed molecules in biological specimens.  322 
 323 
Slide preparation 324 
HeLa cells were plated on glass coverslips and transfected using 325 
Lipofectamine to express fluorescent fusion proteins. 24 h later, cells were 326 
fixed with 4% paraformaldehyde, washed with PBS, quenched with 1 mg/ml 327 
sodium borohydride in PBS and mounted using Mowiol (Calbiochem).  328 
 329 
For virion samples, a drop of 5 μg/ml fibronectin in PBS was added to 330 
coverslips, left for 1 h, removed and allowed to dry before addition of a 331 
suspension of sucrose purified HIV-1 virions (typically 20 μl at a concentration 332 
of an equivalent of 1 x 107 pg p24Gag protein/ml). After 1 h incubation at 37°C, 333 
virions were fixed with 4% paraformaldehyde, quenched, then permeabilized 334 
with 0.2% Triton before staining with labeled Fab fragments and mounting. 335 
Virions were produced by co-transfection of HEK293T cells with pNL4.3/∆Vif 336 
and expression vectors for fluorescent fusion proteins (A3G, CYPA or Vpr). 337 
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 338 
Cy3 labelled Fab fragment generation 339 
To obtain RT specific Fab fragments, we first generated a polyclonal RT 340 
specific antibody in rabbits, with Lampire Biological Laboratories, using full 341 
length RT produced in E. coli. The RT expression plasmid was a kind gift from 342 
Stephen Hughes and purification was performed as reported14,15. Rabbit 343 
serum had titers, as determined by ELISA, of 4.84 x 104 and 3.62 x 105 at day 344 
30 and 50 post injection respectively. Antigen specific antibody was purified 345 
from serum by first enriching IgG fractions using Melon Gel IgG purification 346 
resin (Pierce) and then binding to full length RT isolated from HEK293T cells 347 
and immobilized using the AminoLink Plus Immobilization Kit (Pierce). Bound 348 
antibody was eluted with low pH buffer, neutralized and subsequently used for 349 
Fab fragment preparation and purification using the Fab Micro Preparation Kit 350 
(Pierce). The same kit was used to produce Fab fragments from the anti-351 
p24Gag antibody (mouse monoclonal, 24-28). All steps were carried out 352 
according to the manufacturer’s protocol and resulting products controlled by 353 
SDS-PAGE and Coomassie staining. Lastly, Fab fragments were covalently 354 
labeled with Cy3 using Cy3 Monoreactive Dye (GE Healthcare) and purified 355 
from excess dye by gel filtration (PD MiniTrap G25, GE Healthcare).   356 
 357 
FRET-FLIM instrument 358 
FLIM was used to measure FRET between protein pairs, which allows the 359 
determination of spatial protein interactions16. Time-domain FLIM was 360 
performed with a multi-photon microscope system as described previously16-361 
18.  The system is based on a modified Bio-Rad MRC 1024MP workstation, 362 
comprising a solid-state-pumped femtosecond Ti:Sapphire (Tsunami, 363 
Spectra-Physics) laser system, a focal scan-head and an inverted microscope 364 
(Nikon TE200).  Enhanced detection of the scattered component of the 365 
emitted (fluorescence) photons was afforded by the use of fast response 366 
(Hamamatsu R7401-P) non-descanned detectors, developed in-house, 367 
situated in the re-imaged objective pupil plane. Fluorescence lifetime imaging 368 
capability was provided by time-correlated single photon counting (TCSPC) 369 
electronics (Becker & Hickl, SPC 700). A 40x objective was used throughout 370 
(Nikon, CFI60 Plan Fluor N.A. 1.3) and data collected at 500 ± 20 nm through 371 
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a bandpass filter (Coherent Inc. 35-5040). Images were all acquired at 256 x 372 
256 pixel resolution. Laser power was adjusted to give average photon 373 
counting rates of the order 104 – 105 photons s-1 (0.0001 to 0.001 photon 374 
counts per excitation event) to avoid pulse pile up that can lead to inaccurate 375 
lifetime quantification. Acquisition times up to 300 s at low excitation power 376 
were used to achieve sufficient photon statistics for monoexponential fitting, 377 
while avoiding either pulse pile-up or significant photobleaching. Excitation 378 
was at 890 nm. Widefield acceptor images were acquired using a CCD 379 
camera (Hammamatsu) at <100 ms exposure times. 380 
 381 
FRET data analysis 382 
Bulk measurements of FRET efficiency (i.e. intensity-based methods) cannot 383 
distinguish between an increase in FRET efficiency (i.e. coupling efficiency) 384 
and an increase in FRET population (concentration of FRET species) since 385 
the two parameters are not resolved. The data presented here were analyzed 386 
using a monoexponential decay model, and goodness of fit was confirmed by 387 
determination of chi-squared values close to 1. The FRET efficiency is related 388 
to the molecular separation of donor and acceptor and the fluorescence 389 
lifetime of the interacting fraction by:  390 
 391 
ηfret=(R06/(R06 + r6))=1-τfret/τd 392 
 393 
Where R0 is the Förster radius, r the molecular separation, ηfret is the lifetime 394 
of the interacting fraction and τd the lifetime of the donor in the absence of 395 
acceptor. ηfret and τd can also be taken to be the lifetime of the interacting 396 
fraction and non-interacting fraction, respectively. All data were analysed 397 
using TRI2 software (developed by Paul Barber, King’s College London). Dot 398 
plot data presented here include individual measurements as well as the 399 
mean FRET efficiency from >8 cells (or >5 areas for virion FRET) per sample 400 
+/- SD. Lifetime images of example cells are presented using a pseudocolour 401 
scale whereby blue depicts normal GFP lifetime (no FRET) and red depicts 402 
lower GFP lifetime (areas of FRET). 403 
 404 
Purification of A3G proteins 405 
 13
A3G sequences were subcloned into pVL1392 transfer vector as described 406 
above. Recombinant baculovirus stocks expressing wild type A3G or the 407 
R24A mutant with C-terminal 6xHis tags were prepared using the BaculoGold 408 
Baculovirus Expression System (BD Biosciences) on SF9 monolayer cells, 409 
according to the manufacturer’s protocol. High titer virus stocks were 410 
achieved by 5 rounds of viral amplification on Sf9 monolayer cells at 3 days 411 
each. Proteins were expressed in suspension Sf9 insect cells, cultured in 412 
Sf900 II medium (Gibco) supplemented with 1% Pen/Strep (Gibco), by 413 
infection with recombinant virus. Three days after infection cells were lysed in 414 
50 mM Tris HCl pH 8.8, 0.5% NP40, 200 mM NaCl, 10% glycerol, 1mM DTT 415 
supplemented with 50 μg/ml RNase A (Sigma) and protease inhibitor (Roche), 416 
and incubated for 10 min on ice. The lysate was homogenized by two 10 s 417 
sonication steps before incubation for 1 h at 25°C with slow rocking for 418 
complete RNA digestion. Lysates were clarified by centrifugation at 1000 x g 419 
for 10 min at 4°C, and adjusted to 0.6 M NaCl, before addition of nickel-420 
nitrilotriacetic acid-agarose (Novagen). Proteins were allowed to bind for 2 h 421 
at 4°C while rotating. The suspension was centrifuged at 500 x g for 10 min at 422 
4°C, the supernatant discarded, and lysis buffer added to the beads. The 423 
suspension was loaded onto a poly-prep chromatography column (Bio-Rad) 424 
and washed 5 times with 5 ml of wash buffer (50 mM Tris HCl pH 8.8, 125 425 
mM NaCl, 10% glycerol, 1 mM DTT, 1% NP40, 50 mM imidazole) before 426 
elution with 50 mM Tris HCl pH 8.8, 125 mM NaCl, 10% glycerol, 1 mM DTT, 427 
1% NP40, 200 mM imidazole. To avoid protein precipitation off the column, 428 
elution was performed with 1.2 ml elution buffer into 5 ml buffer (50 mM Tris 429 
HCl pH 8.8, 125 mM NaCl, 10% glycerol, 1 mM DTT, 1% NP40). The solution 430 
was then loaded onto a DEAE-FF sepharose column (GE Healthcare) on an 431 
AKTA Purifier 10 (Pharmacia) and eluted with a gradient (0-100%) of buffer A 432 
(50 mM Tris HCl pH 8.8, 0.5% NP40, 50 mM NaCl, 10% glycerol, 1 mM DTT) 433 
and buffer B (50 mM Tris HCl pH 8.8, 0.5% NP40, 1 M NaCl, 10% glycerol, 1 434 
mM DTT). Peak fractions were dialyzed into a suitable buffer, concentration 435 
determined by Bradford assay with BSA standards, and homogeneity judged 436 
by Coomassie staining (see Supplemental Figure 3 and 8). 437 
 438 
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